XML 237 R50.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Operating Segments (Tables) | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2024 | Dec. 31, 2023
Operating Segments [Abstract] |  |
Schedule of Operating Segments | The Group’s CODM is the CEO of the Company.
|  | Six months ended June 30, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 840 |  |  | $ | 840 |
Total |  |  | - |  |  |  | 840 |  |  |  | 840 |
Segment loss (gain) |  |  | 3,040 |  |  |  | 487 |  |  |  | 3,527 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 208 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | - |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (51 | )
Tax expense (income) |  |  |  |  |  |  |  |  |  |  | (5 | )
Loss |  |  |  |  |  |  |  |  |  |  | 3,679 |
|  | Six months ended June 30, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,972 |  |  | $ | 1,972 |
Total |  |  | - |  |  |  | 1,972 |  |  |  | 1,972 |
Segment loss (gain) |  |  | 2,772 |  |  |  | 195 |  |  |  | 2,967 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 99 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | - |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (147 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 13 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,932 |
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 414 |  |  |  | 5,773 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | 1,042 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
|  | As of June 30, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 6,834 |  |  | $ | 3,648 |  |  | $ | 10,482 |
Segment Liabilities |  | $ | 1,742 |  |  | $ | 84 |  |  | $ | 1,826 |
|  | As of June 30, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 4,290 |  |  | $ | 5,602 |  |  | $ | 9,892 |
Segment Liabilities |  | $ | 2,741 |  |  | $ | 373 |  |  | $ | 3,114 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |
| The Group’s CODM is the CEO of the Company.
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 414 |  |  |  | 5,773 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | 1,042 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
|  | Year ended December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,347 |  |  | $ | 1,347 |
Total |  |  | - |  |  |  | 1,347 |  |  |  | 1,347 |
Segment loss |  |  | 8,405 |  |  |  | (118 | ) |  |  | 8,287 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 109 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (5,818 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 14 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,592 |
|  | Year ended December 31, 2021 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | - |  |  | $ | - |
Total |  |  | - |  |  |  | - |  |  |  | - |
Segment loss |  |  | 5,768 |  |  |  | - |  |  |  | 5,768 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | 21 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,789 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |
|  | As of December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 9,664 |  |  | $ | 941 |  |  | $ | 10,605 |
Segment Liabilities |  | $ | 4,021 |  |  | $ | 135 |  |  | $ | 4,156 |

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration